This week's FierceBiotech is brought to you by Rho.

Trouble viewing? Click here.


Hi Alayna,

Right-to-Try has been in the news a lot recently, but what does it actually mean for product sponsors? This white paper explores both Right-to-Try legislation and existing Expanded Access Programs, including:

  • Understanding sponsor responsibilities under these programs and when products may be eligible for these programs
  • Evaluating options such as treatment protocols, treatment INDs, and emergency use
  • Discussing development risks associated with participation in these programs

Download this white paper



If you no longer wish to receive communications from Rho, please opt out here.

Want to reach 137,000+ FierceBiotech subscribers with your own message?
Contact [email protected] or call 202-824-5074.

You are currently subscribed as [email protected]
If you no longer wish to receive communications from FierceBiotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

FierceMarkets, a division of Questex, LLC
1900 L St. NW Suite 400 
Washington, DC 20036